The study shows that during HIV heterosexual transmission, when only a few viruses in the infected partner are transmitted, the more fit viruses are preferred. These findings help to explain how viral fitness affects HIV transmission and suggests that vaccines that weaken the virus could significantly reduce transmission and confer long-term clinical benefits.
K-RITH successfully secured its first direct grant from the National Institutes of Health (NIH) at the end of June 2014 for the support of a project entitled ‘Ongoing HIV replication as a CNS persistence mechanism in the face of cART’.
Scientist-in-Residence Jacques Grosset was amongst a group of K-RITH scientists who presented at the 4th South African TB Conference held recently at the ICC in Durban. Grosset's talk was entitled 'Dose ranging activity of Clofazamine in murine model of tuberculosis.'
A leading global health advocate, Barry Bloom investigates how the immune system fights against tuberculosis and how that response can be harnessed to develop new vaccines and more effective treatments. As a member of the K-RITH Scientific Advisory Board, Bloom visited K-RITH in May this year to see the organisation operating at full capacity and to learn about the exciting research underway.
Professor Lynn Morris, Chief Specialist Scientist and head of the HIV Virology laboratories within the Centre of HIV & STI’s at NICD will be speaking on 'Prospects for an antibody-based HIV vaccine' at the August K-RITH Seminar.
Director for UKZN's Africa Centre for Health and Population Studies, Professor DeenanPillay will be speaking on 'The biology, transmission and impact of HIV drug resistance' at the June K-RITH Seminar.